InMed Pharmaceuticals Files S-1 for Potential Offering

TL;DR

InMed Pharma just filed an S-1, looks like they're gearing up for a stock offering.

AI Summary

InMed Pharmaceuticals Inc. filed an S-1 registration statement on December 23, 2024, indicating plans to offer securities. The company, incorporated in British Columbia, is based in Vancouver and operates in the pharmaceutical preparations sector. This filing is a preliminary step for a potential public offering, though specific dollar amounts and dates for the offering are not yet detailed.

Why It Matters

This S-1 filing signals InMed Pharmaceuticals' intention to raise capital through the public markets, which could fund its drug development pipeline or other corporate initiatives.

Risk Assessment

Risk Level: medium — As a pharmaceutical company filing an S-1, InMed is likely in the early stages of development or seeking significant funding, which carries inherent risks associated with clinical trials, regulatory approvals, and market acceptance.

Key Numbers

• 333-284029 — SEC File Number (Identifies this specific registration statement with the SEC.)
• 0630 — Fiscal Year End (Indicates the end of the company's fiscal year for financial reporting.)

Key Players & Entities

• InMed Pharmaceuticals Inc. (company) — Registrant
• December 23, 2024 (date) — Filing Date
• British Columbia (jurisdiction) — State of Incorporation
• Vancouver (location) — Principal Business Address
• 2834 (sic_code) — Pharmaceutical Preparations
• Netta Jagpal (person) — Chief Financial Officer

FAQ

Key Financial Figures

• $10,000,000 — reholder. However, we may receive up to $10,000,000 in aggregate gross proceeds from sales
• $4.40 — shares on the Nasdaq Capital Market was $4.40 per share (rounded to the nearest hundr
• $1.00 — nk of Canada daily rate of exchange was $1.00 = C$1.4365 or C$1.00 = $0.6961. ii P
• $1.4365 — ada daily rate of exchange was $1.00 = C$1.4365 or C$1.00 = $0.6961. ii PROSPECTUS S
• $0.6961 — change was $1.00 = C$1.4365 or C$1.00 = $0.6961. ii PROSPECTUS SUMMARY This summar
• $7.7 million — acturing technologies. Our net loss was $7.7 million and $7.9 million for the years ended Ju
• $7.9 million — gies. Our net loss was $7.7 million and $7.9 million for the years ended June 30, 2024 and 2
• $109.1 million — tion, we have an accumulated deficit of $109.1 million as of June 30, 2024, which includes all
• $1.235 b — total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal
• $700.0 million — shares held by non-affiliates exceeded $700.0 million as of the last business day of the seco
• $1.0 billion — date on which we have issued more than $1.0 billion in non-convertible debt securities duri
• $250 million — common shares held by non-affiliates is $250 million or more, as measured on the last busine
• $100 million — r, or our annual revenues are less than $100 million during the most recently completed fisc
• $700 million — common shares held by non-affiliates is $700 million or more, as measured on the last busine
• $1,000,000 — hares will be equal to the lower of (i) $1,000,000 of common shares and (ii) such amount a

Filing Documents

• ea0225519-s1_inmedpharma.htm (S-1) — 344KB
• ea022551901ex5-1_inmed.htm (EX-5.1) — 12KB
• ea022551901ex23-1_inmed.htm (EX-23.1) — 2KB
• ea022551901ex-fee_inmed.htm (EX-FILING FEES) — 14KB
• image_001.jpg (GRAPHIC) — 15KB
• ex5-1_001.jpg (GRAPHIC) — 11KB
• 0001213900-24-111992.txt ( ) — 410KB

From the Filing

As filed with the Securities and Exchange Commission on December 23, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INMED PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) British Columbia 2834 98-1428279 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Suite 1445 – 885 West Georgia St. Vancouver, British Columbia, Canada V6C 3E8 (604) 669-7207 (Address, including zip code and telephone number, including area code, of registrant’s principal executive offices) Registered Agent Solutions, Inc. 1100 H Street NW, Suite 840 Washington, D.C. 20005 (888) 705-7274 (Name, address, including zip code, and telephone number, including area code, of agent for service) with copies to: Netta Jagpal Chief Financial Officer InMed Pharmaceuticals Inc. Suite 1445 – 885 West Georgia St. Vancouver, British Columbia, Canada V6C 3E8 (604) 669-7207 Jared D. Kaplan Trevor Zeyl Norton Rose Fulbright US LLP 1045 W. Fulton Street Suite 1200 Chicago, IL 60607 (312) 964-7754 Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement. If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer: Accelerated reporting company: Emerging Growth Company: If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act The registrant hereby amends this registration specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission acting pursuant to said Section 8(a), may determine. The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration and it is not soliciting offers to buy these securities in any state or other jurisdiction where the offer or sale is not permitted. PROSPECTUS 3,000,000 Common Shares This prospectus relates to the offer and resale by the selling shareholder identified herein, or the Selling Shareholder, or any of its pledgees, donees, assignees and successors-in-interest, or collectively, the permitted transferees, of up to 3,000,000 of our common shares, no par value per share, or the common shares. The common shares to which this prospectus relates consists of up to 3,000,000 common shares that we may sell to the Selling Shareholder, from time to time after the date of this prospectus, in our sole and absolute discretion, pursuant to the Standby Equity Purchase Agreement, dated December 13, 2024, or the SEPA. The Selling Shareholder is an underwriter within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended, or the Securities Act. The registration of the common shares hereunder does not mean that the Selling Shareholder will actually purchase, or that the Company will actually issue and sell, all or any of the 3,000,000 common shares being registered pursuant to the registration statement on Form S-1 under the Securities Act to which this prospectus relates. We are not selli

View Full Filing

View this S-1 filing on SEC EDGAR